Clin2
NCT07314229Possibly a fitRecruiting

Breathing limits during exercise in cystic fibrosis patients on ETI

Cystic Fibrosis (CF)Mucoviscidosis

Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.

This study measures how often people with cystic fibrosis who take elexacaftor-tezacaftor-ivacaftor (ETI) experience breathing limitations during exercise and what factors are linked to this.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
130 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older
  • You have cystic fibrosis
  • You are being treated at the cystic fibrosis centers in Lille or Créteil, France
  • You are currently taking elexacaftor-tezacaftor-ivacaftor (ETI) therapy
  • You have health insurance (social security) coverage
  • You are able to understand the study and give written consent

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07629986Recruiting
How antibiotics work in cystic fibrosis patients on ETI therapy

This study measures how antibiotics are processed by the body in people with cystic fibrosis who are taking a combination drug called elexacaftor/tezacaftor/ivacaftor (ETI). Understanding this helps doctors prescribe the right antibiotic doses for patients on this newer treatment.

Roscoff
NCT07363304Recruiting
How ETI therapy affects body and gut in cystic fibrosis

This study looks at how the triple combination therapy (elexacaftor/tezacaftor/ivacaftor, or ETI) affects your body's metabolism, epigenetics, and gut bacteria in people with cystic fibrosis. It aims to understand the broader health benefits of this treatment.

Bari, Bari
NCT07148739Recruiting· Phase 4
Ensuring Best Access to CF Treatment

This study tests whether people with cystic fibrosis who are already on a triple combination CFTR modulator can stay on their treatment without interruptions or problems. It aims to make sure everyone gets the best, most consistent treatment for their CF.

Birmingham, Alabama
NCT07692594Not yet recruiting
Heart and blood vessel health in cystic fibrosis

This study looks at how cystic fibrosis affects the heart and blood vessels in people taking CFTR modulators (like Trikafta). It also compares results to healthy adults to understand if the medicine helps protect the heart.

Liverpool
NCT07027553Not yet recruiting
Remote exercise program for heart health in cystic fibrosis

This trial tests whether a remote exercise program can help people with cystic fibrosis become more active and improve their heart health. You would exercise from home with guidance from a research team.

Bath
NCT07508904Recruiting
Exercise effects in children with cystic fibrosis

This study tests whether a specific exercise program can improve muscle strength, breathing, and fitness in children with cystic fibrosis who are stable and able to exercise.

Lahore

Hear when a new Cystic Fibrosis (CF) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.